ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
03/31/201516:39:35Statement of Changes in Beneficial Ownership (4)
03/31/201513:40:51Vital Signs Show the Market for Health-Deals Is In the Pink
03/31/201501:12:08Defensive Sectors Lead Hesitant Market, But Traders Honor Long-Standing...
03/27/201516:10:12Current Report Filing (8-k)
03/27/201510:40:43Valeant closes equity offering
03/27/201510:09:00Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common...
03/27/201510:09:00Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common...
03/27/201507:36:37Current Report Filing (8-k)
03/26/201514:11:57Why Synergy Pharmaceuticals, Inc. Is Surging Higher Today.
03/25/201519:56:37Lean Recipe Fuels Food Deals--Update
03/25/201511:57:13Statement of Beneficial Ownership (sc 13d)
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/22/201519:57:32Proceedings / Highlights From The Law Blog
03/18/201515:54:47Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
03/18/201506:04:06Current Report Filing (8-k)
03/17/201519:03:08Valeant prices equity offering
03/17/201509:00:00Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common...
03/17/201509:00:00Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common...
03/16/201519:47:24Valeant Raises Offer To $173/Share In New Deal for Salix--6th...
03/16/201519:36:19Valeant Raises Offer To $173/Share In New Deal for Salix--6th...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad